OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors. Methods: We conducted a scientific literature search using the PubMed database up to July 2018 with the terms “MEK inhibitors” with a “review” filter and “MEK inhibitors” with a “clinical trials” filter. Phase I–III experimental studies and reviews were selected. Current principles and techniques for diagnosing and managing MEK inhibitor retinopathy and other OAEs are discussed. Results: In patients treated with MEK inhibitors, including asymptomatic patients, OAEs occur with an incidence of up to 90%. Mild to severe ophthalmic toxicities are described, including visual disturbances, a 2-line decrease in Snellen visual acuity, dry eye symptoms, ocular adnexal abnormalities, visual field defects, panuveitis, and retinal toxicities, such as different degrees of MEK-associated retinopathy, vascular injury, and retinal vein occlusion. Conclusion: MEK inhibitors can lead to different degrees of retinal, uveal, and adnexal OAE, causing visual disturbances or discomfort. One of the most relevant OAE of MEK therapy is MEK inhibitor–associated retinopathy (MEKAR), which is usually mild, self-limited, and may subside after continuous use of the drug for weeks or months, or discontinuation, thereby restoring the normal visual function of the retina, with some exceptions. Ocular adverse events are often associated with other systemic adverse effects that can modify the dosage of treatment, so the communication with the oncologist is fundamental.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Much of the current knowledge on the ocular effects of systemic pharmacological intervention in the MAPK signaling pathways has been gained from studies on cancer patients treated with MEK1/2 inhibitors, B-Raf inhibitors or a combination of both [ 213 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [213]
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
The Retinal Pigment Epithelium in Visual Function
Strauss, O. (2005) · Physiological Reviews · doi:10.1152/physrev.00021.2004 · Cited by 2,828
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cited by
Moertel, C. L., Hirbe, A. C., Shuhaiber, H. H., Bielamowicz, K., Sidhu, A., Viskochil, D. H., Weber, M., Lokku, A., Smith, L. M., Foreman, N. K., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01034 · Cited by 139
Gross, A. M., Dombi, E., Wolters, P. L., Baldwin, A. M., Dufek, A., Herrera, K. R., Martin, S. C., Derdak, J., Heisey, K., Whitcomb, P. O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad086 · Cited by 129
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
Klesse, L. J., Jordan, J. T., Radtke, H. B., Rosser, T. L., Schorry, E. K., Ullrich, N. J., Viskochil, D. H., Knight, P. B., Plotkin, S. R., & Yohay, K. H. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0069 · Cited by 125
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
de Blank, P. M. K., Gross, A. M., Akshintala, S., Blakeley, J. O., Bollag, G. E., Cannon, A. D., Dombi, E., Fangusaro, J., Gelb, B. D., Hargrave, D. R., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac165 · Cited by 121
Current treatment of optic nerve gliomas
Farazdaghi, M. K., Katowitz, W. R., & Avery, R. A. (2019) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000587 · Cited by 99
Metadata
- Authors
- Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L.
- Affiliations
- Universidad de Zaragoza (ES)
- Department of Ophthalmology, Miguel Servet University Hospital, IIS-Aragon, Zaragoza, Spain; and
- Corresponding author
- Méndez-Martínez, Silvia
- Calvo, Pilar
- Pablo, Luis
- Venue
- Retina
- Published
- 2019-08
- Volume
- 39
- Issue
- 8
- Pages
- 1435-1450
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2912028213
- Cited by
- 117
- References
- 112
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 16 · 2023: 19 · 2022: 22 · 2021: 18 · 2020: 9 · 2019: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Keywords
- MEK inhibitors, ocular adverse effects, retinal toxicity, BRAF-mutant melanoma, MAPK inhibitors, retinal vein occlusion, panuveitis, dry eye, visual disturbances, drug toxicity management
- MeSH terms
- Humans, Retinal Diseases, Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. https://app.cochat.ai/papers/10.1097/iae.0000000000002451
- The paper
- Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019). OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina. https://doi.org/10.1097/iae.0000000000002451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.